Head-to-head · free

Genmab vs iRhythm Technologies, Inc.

GMAB vs IRTC — return on capital, cash generation, margins and balance sheet side by side.

GMAB

3 / 4

measures where GMAB leads

IRTC

1 / 4

measures where IRTC leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureGMABIRTC · FY2025
Revenue—$747.1M
Net income—(44.6M)
Revenue growth (yearly, multi-year)—23.3%
Free cash flow—$34.5M
Free cash flow margin—4.6%
Net cash / (debt)——
ROIC10.1%—
Return on equity17.5%-36.6%
Gross margin93.6%70.6%
Operating margin33.6%-6.7%
Net debt / EBITDA3.13x-13.37x

Figures are as reported by each company; latest fiscal year shown.

Where Genmab's cash went

Not reported yet.

Full GMAB profile →

Where iRhythm Technologies, Inc.'s cash went (FY2025)

Capital spending
$46.3M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full IRTC profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons